1. A glucocorticoid suppresses the synthesis of prostaglandins, thromboxanes, and leukotrienes simultaneously. Which single upstream action best accounts for this broad, parallel suppression of all eicosanoid classes?
A) Induction of annexin-A1 (lipocortin-1), which inhibits cytosolic phospholipase A2 and reduces the release of arachidonic acid available to all downstream eicosanoid pathways
B) Direct competitive inhibition of cyclooxygenase-2 (COX-2) at its catalytic site
C) Irreversible acetylation of the cyclooxygenase enzyme active site
D) Selective blockade of the 5-lipoxygenase (5-LOX) pathway only
E) Inhibition of thromboxane synthase in platelets
ANSWER: A
Rationale:
Glucocorticoids induce annexin-A1 (lipocortin-1), an endogenous inhibitor of cytosolic phospholipase A2 (PLA2). Because PLA2 releases arachidonic acid from membrane phospholipids, inhibiting it reduces substrate availability for both the cyclooxygenase and the lipoxygenase pathways at once, which suppresses prostaglandin, thromboxane, and leukotriene synthesis in parallel. This upstream action is what distinguishes the anti-inflammatory breadth of glucocorticoids from agents acting on a single downstream enzyme, making Option A correct.
Option B: Option B is incorrect because direct catalytic inhibition of COX-2 describes the mechanism of NSAIDs, not glucocorticoids; glucocorticoids reduce COX-2 at the transcriptional level rather than by binding the catalytic site.
Option C: Option C is incorrect because irreversible acetylation of the cyclooxygenase active site is the specific mechanism of aspirin and would affect only the cyclooxygenase pathway, not the leukotriene pathway.
Option D: Option D is incorrect because selective 5-LOX blockade would suppress leukotrienes alone and would not explain the parallel reduction in prostaglandins and thromboxanes.
Option E: Option E is incorrect because thromboxane synthase inhibition acts at a single distal step downstream of cyclooxygenase and cannot account for simultaneous suppression of all eicosanoid classes.
2. Six hours after starting high-dose systemic glucocorticoid therapy, a patient's absolute neutrophil count has risen 2- to 3-fold with no clinical signs of infection. Which mechanism best explains this neutrophilia?
A) A surge in granulocyte-macrophage colony-stimulating factor (GM-CSF) driving accelerated granulopoiesis
B) Enhanced neutrophil antimicrobial function and respiratory burst activity
C) Demargination of neutrophils from the vascular endothelium combined with accelerated release of mature neutrophils from bone marrow storage pools
D) An acute bacterial infection unmasked by immunosuppression
E) Expansion of immature band forms reflecting a true left shift
ANSWER: C
Rationale:
Glucocorticoid-induced neutrophilia results from redistribution, not increased production or improved function. Glucocorticoids suppress neutrophil surface adhesion molecules (L-selectin and the beta-2 integrin Mac-1), reducing margination to the vascular endothelium, which normally sequesters roughly half the circulating neutrophil pool, and they accelerate release of mature neutrophils from marrow storage. The net effect is a transient expansion of the circulating pool with no enhancement of antimicrobial capacity, making Option C correct.
Option A: Option A is incorrect because the neutrophilia does not depend on GM-CSF-driven granulopoiesis; it appears within hours, too rapidly to reflect new marrow production.
Option B: Option B is incorrect because neutrophil function is not enhanced by glucocorticoids; the higher count does not improve antimicrobial defense and may coexist with impaired host immunity.
Option D: Option D is incorrect because this predictable pharmacological neutrophilia occurs in the absence of infection, and an elevated count in a steroid-treated patient cannot be used as a reliable marker of bacterial infection.
Option E: Option E is incorrect because the released cells are mature neutrophils from the storage pool rather than immature band forms, so a true left shift is not the expected pattern.
3. A critically ill patient with cerebral edema and volume overload requires a glucocorticoid that will not aggravate sodium and fluid retention. Which property of dexamethasone makes it the preferred agent in this setting?
A) A short biologic half-life permitting rapid titration
B) Negligible mineralocorticoid activity, so it does not promote renal sodium and water retention
C) High mineralocorticoid potency that supports blood pressure in shock
D) Rapid hepatic clearance that prevents drug accumulation
E) Selective action on mineralocorticoid receptors in the distal nephron
ANSWER: B
Rationale:
Dexamethasone is a synthetic glucocorticoid with high glucocorticoid potency and essentially no mineralocorticoid activity. Because it does not stimulate renal sodium and water retention, it avoids worsening volume overload in patients who are already fluid-overloaded or edematous, which is why it is favored for cerebral edema and was selected in critical-illness trials where fluid retention is undesirable. This makes Option B correct.
Option A: Option A is incorrect because dexamethasone has a long biologic duration of action (roughly 36 to 54 hours), not a short half-life; its long action is in fact what permits once-daily dosing.
Option C: Option C is incorrect because dexamethasone has negligible, not high, mineralocorticoid potency, so it does not support blood pressure through sodium retention.
Option D: Option D is incorrect because dexamethasone is not characterized by rapid hepatic clearance; its prolonged biologic effect makes titration and discontinuation slower, not faster.
Option E: Option E is incorrect because dexamethasone acts predominantly at the glucocorticoid receptor, not selectively at mineralocorticoid receptors in the distal nephron.
4. Glucocorticoids broadly suppress the acute inflammatory transcriptome. Which transcription factor is the principal master regulator whose inhibition accounts for much of this effect?
A) Hypoxia-inducible factor 1-alpha (HIF-1alpha)
B) Sterol regulatory element-binding protein (SREBP)
C) Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
D) Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB)
NF-kappaB is the master regulator of the acute inflammatory transcriptome, driving transcription of cytokines, adhesion molecules, and inducible enzymes. Glucocorticoids inhibit it through several parallel actions: the activated glucocorticoid receptor tethers to the p65 subunit, induction of IkappaB-alpha sequesters NF-kappaB in the cytoplasm, and recruitment of histone deacetylase 2 (HDAC2) closes the chromatin at inflammatory gene promoters. This central role makes Option D correct.
Option A: Option A is incorrect because HIF-1alpha governs the cellular response to hypoxia rather than serving as the master driver of the acute inflammatory program.
Option B: Option B is incorrect because SREBP regulates lipid and cholesterol biosynthesis, not inflammatory gene transcription.
Option C: Option C is incorrect because PPAR-gamma is itself anti-inflammatory and a target of thiazolidinediones; it is not the pro-inflammatory factor that glucocorticoids inhibit.
Option E: Option E is incorrect because Nrf2 drives antioxidant gene expression and is not the principal pro-inflammatory transcription factor suppressed by glucocorticoids.
5. Within hours of a single pharmacological glucocorticoid dose, circulating T lymphocytes fall by 70 to 90 percent and then recover within about 24 hours. Which mechanism best explains this rapid, reversible lymphopenia in humans?
A) Massive complement-mediated lysis of circulating T cells
B) Irreversible clonal deletion of all peripheral T cell populations
C) Permanent thymic involution preventing T cell output
D) Suppression of bone marrow lymphopoiesis halting new lymphocyte production
E) Redistribution of lymphocytes from blood into lymphoid tissues through altered homing receptor expression
ANSWER: E
Rationale:
In most human clinical contexts, glucocorticoid-induced lymphopenia is produced by redistribution rather than cell killing. Glucocorticoid receptor-mediated changes in homing receptor expression and cytokine signals redirect circulating T lymphocytes, B lymphocytes, and natural killer cells from the blood into lymphoid tissues such as spleen, lymph nodes, and bone marrow, and this shift reverses within about 24 hours of a single dose. This redistribution mechanism makes Option E correct.
Option A: Option A is incorrect because complement-mediated lysis is not the mechanism; the cells are sequestered, not destroyed, which is why the count recovers so quickly.
Option B: Option B is incorrect because the lymphopenia is rapidly reversible, which is incompatible with irreversible clonal deletion of peripheral T cells.
Option C: Option C is incorrect because thymic involution does not explain an acute change occurring within hours, and the effect is not permanent.
Option D: Option D is incorrect because suppression of marrow lymphopoiesis would produce a slow decline over days to weeks rather than the rapid, reversible fall observed; the speed of recovery points to redistribution.
6. Inhaled corticosteroid (ICS) agents are designed to maximize airway drug concentration while minimizing systemic exposure. Which agent is characterized by the highest topical anti-inflammatory potency together with the lowest systemic bioavailability among commonly used ICS?
A) Fluticasone propionate
B) Hydrocortisone
C) Prednisone
D) Triamcinolone acetonide given intra-articularly
E) Oral dexamethasone
ANSWER: A
Rationale:
Fluticasone propionate has the highest topical anti-inflammatory potency and the lowest systemic bioavailability among commonly used inhaled corticosteroids. Its swallowed fraction undergoes near-complete first-pass hepatic metabolism (roughly 1 percent gastrointestinal bioavailability), and only a portion of the inhaled fraction reaches the systemic circulation, which underlies the favorable local-to-systemic ratio that defines ICS pharmacology. This makes Option A correct.
Option B: Option B is incorrect because hydrocortisone is a systemic and topical agent of relatively low potency, not an inhaled agent selected for airway delivery.
Option C: Option C is incorrect because prednisone is an orally administered systemic glucocorticoid with substantial systemic exposure, the opposite of the ICS design goal.
Option D: Option D is incorrect because intra-articular triamcinolone acetonide is a depot injection for joint disease, not an inhaled agent, and is not characterized by minimized systemic bioavailability through inhalation.
Option E: Option E is incorrect because oral dexamethasone is a high-potency systemic glucocorticoid with high systemic exposure and is not used as an inhaled airway-targeted agent.
7. A patient on chronic glucocorticoid therapy is undergoing major surgery and requires perioperative stress-dose coverage to prevent adrenal crisis. Which glucocorticoid is the standard agent used for intravenous stress-dose supplementation in this setting?
A) Dexamethasone
B) Fludrocortisone
C) Hydrocortisone
D) Beclomethasone dipropionate
E) Clobetasol propionate
ANSWER: C
Rationale:
Hydrocortisone is the standard agent for perioperative stress-dose coverage. It is the synthetic equivalent of endogenous cortisol, has both glucocorticoid and mineralocorticoid activity that approximates the physiological stress response, and is given intravenously (for example, 100 mg at induction followed by 50 mg every 8 hours for major surgery) with intramuscular dosing available when intravenous access is unavailable. This makes Option C correct.
Option A: Option A is incorrect because dexamethasone, while a potent glucocorticoid, lacks mineralocorticoid activity and its long duration makes titration and discontinuation around surgery less convenient; it is not the conventional stress-dose agent.
Option B: Option B is incorrect because fludrocortisone is a potent mineralocorticoid used for chronic mineralocorticoid replacement, not as the primary intravenous perioperative stress glucocorticoid.
Option D: Option D is incorrect because beclomethasone dipropionate is an inhaled corticosteroid for airway disease and has no role in intravenous perioperative coverage.
Option E: Option E is incorrect because clobetasol propionate is a superpotent topical agent for skin disease and cannot provide systemic stress-dose coverage.
8. In a patient receiving systemic glucocorticoid therapy, a markedly suppressed blood eosinophil count is best interpreted as which of the following?
A) Evidence of a superimposed bacterial infection
B) A sign of active glucocorticoid receptor engagement and adequate drug effect
C) An indication that the dose is excessive and should be reduced
D) Evidence of new allergic or parasitic disease
E) A marker of bone marrow failure requiring drug discontinuation
ANSWER: B
Rationale:
Glucocorticoids drive eosinophil apoptosis and a rapid fall in the blood eosinophil count, and this eosinopenia is one of the most sensitive and fastest indicators of glucocorticoid bioactivity; historically it was used to demonstrate receptor engagement in pharmacodynamic studies. In a treated patient, a suppressed eosinophil count therefore indicates active glucocorticoid receptor engagement and adequate drug effect, making Option B correct.
Option A: Option A is incorrect because eosinopenia is the expected pharmacological effect of the drug rather than a sign of bacterial infection.
Option C: Option C is incorrect because eosinopenia reflects the intended drug action and is not by itself evidence of overdosing; conversely, a rising eosinophil count in a patient who should be suppressed raises concern for non-adherence or inadequate dosing.
Option D: Option D is incorrect because new allergic or parasitic disease would tend to raise, not lower, the eosinophil count.
Option E: Option E is incorrect because the low eosinophil count reflects redistribution and apoptosis from drug effect, not marrow failure, and does not mandate discontinuation.
9. Topical glucocorticoids are classified into seven potency classes by the vasoconstrictor (skin-blanching) assay. Which statement correctly describes the Class I category?
A) Class I agents are the lowest-potency preparations safe for facial and intertriginous use
B) Class I refers to hydrocortisone 1 percent and similar mild agents suitable for children
C) Class I agents are intermediate-potency preparations for routine truncal use
D) Class I agents are the superpotent preparations (such as clobetasol propionate) intended for short-term use on limited body surface area
E) Class I designation reflects vehicle type rather than glucocorticoid potency
ANSWER: D
Rationale:
In the seven-class topical potency scheme based on the McKenzie-Stoughton vasoconstrictor assay, Class I denotes the superpotent agents, such as clobetasol propionate 0.05 percent and halobetasol propionate. These should be used for no more than about 2 consecutive weeks on limited body surface area and avoided on the face, axillae, groin, and intertriginous skin because of the risk of atrophy and systemic absorption. This makes Option D correct.
Option A: Option A is incorrect because the lowest-potency, face-safe agents are Class VI to VII, not Class I.
Option B: Option B is incorrect because hydrocortisone 1 percent is a low-potency Class VI to VII agent rather than Class I.
Option C: Option C is incorrect because Class I is superpotent, not intermediate potency.
Option E: Option E is incorrect because the potency class reflects glucocorticoid potency measured by skin blanching, whereas vehicle (ointment, cream, lotion) is a separate pharmacological consideration that modifies penetration independently of class.
10. Patients with chronic obstructive pulmonary disease (COPD) and active smokers often show reduced responsiveness to glucocorticoids at the cellular level. Which mechanism best explains this relative glucocorticoid resistance?
A) Oxidative stress from cigarette smoke inactivates histone deacetylase 2 (HDAC2), impairing the glucocorticoid receptor's ability to recruit HDAC2 and switch off inflammatory genes
B) Cigarette smoke upregulates annexin-A1, saturating the anti-inflammatory pathway
C) Smoking increases glucocorticoid receptor density, causing receptor desensitization
D) Tobacco exposure enhances IkappaB-alpha synthesis, blocking glucocorticoid entry into the nucleus
E) Smoke constituents irreversibly acetylate cyclooxygenase, bypassing glucocorticoid control
ANSWER: A
Rationale:
One of the parallel mechanisms by which glucocorticoids suppress NF-kappaB-driven inflammatory genes is recruitment of histone deacetylase 2 (HDAC2) to inflammatory gene promoters, which reverses the histone acetylation that keeps those genes transcriptionally active. In COPD and in smokers, oxidative stress from cigarette smoke causes oxidative modification and inactivation of HDAC2 in airway macrophages, so the glucocorticoid receptor cannot effectively recruit functional HDAC2, and corticosteroid responsiveness falls. This makes Option A correct.
Option B: Option B is incorrect because cigarette smoke does not produce resistance by upregulating annexin-A1; annexin-A1 induction is part of the normal anti-inflammatory response, not a cause of resistance.
Option C: Option C is incorrect because the resistance is not explained by increased receptor density causing desensitization; the defect lies downstream at the HDAC2 step.
Option D: Option D is incorrect because enhanced IkappaB-alpha would, if anything, reduce NF-kappaB activity and does not describe the smoke-related resistance mechanism.
Option E: Option E is incorrect because irreversible acetylation of cyclooxygenase is the aspirin mechanism and is unrelated to glucocorticoid resistance in airway cells.
11. Why do glucocorticoids produce a broader anti-eicosanoid effect than non-steroidal anti-inflammatory drugs (NSAIDs)?
A) Glucocorticoids inhibit cyclooxygenase more potently than NSAIDs do
B) NSAIDs block both cyclooxygenase and lipoxygenase, while glucocorticoids block only cyclooxygenase
C) Glucocorticoids act upstream by limiting arachidonic acid release through phospholipase A2 inhibition, suppressing prostaglandins, thromboxanes, and leukotrienes together, whereas NSAIDs block only the cyclooxygenase pathway
D) NSAIDs suppress cytokine gene transcription, an effect glucocorticoids lack
E) Glucocorticoids and NSAIDs act at the identical enzymatic step with equal spectrum
ANSWER: C
Rationale:
Glucocorticoids reduce arachidonic acid availability at the top of the eicosanoid cascade by inducing annexin-A1, which inhibits phospholipase A2. Because arachidonic acid is the shared substrate for both the cyclooxygenase and lipoxygenase pathways, limiting its release suppresses prostaglandins, thromboxanes, and leukotrienes simultaneously. NSAIDs, by contrast, inhibit only cyclooxygenase and leave leukotriene production intact, so the glucocorticoid effect is broader. This makes Option C correct.
Option A: Option A is incorrect because glucocorticoids do not act by directly inhibiting the cyclooxygenase enzyme; their breadth comes from an upstream substrate-limiting action, not greater catalytic potency.
Option B: Option B is incorrect because it reverses the actual pharmacology: NSAIDs block only cyclooxygenase, while glucocorticoids affect both pathways through upstream substrate limitation.
Option D: Option D is incorrect because cytokine gene transcriptional suppression is a glucocorticoid property, not an NSAID property.
Option E: Option E is incorrect because the two drug classes do not act at the same step or with the same spectrum; that is precisely why their anti-inflammatory breadth differs.
12. A large platform trial showed that dexamethasone reduced mortality in hospitalized patients with COVID-19. In which patient group was the mortality benefit concentrated?
A) All hospitalized patients regardless of oxygen requirement
B) Patients with mild disease not requiring hospitalization
C) Patients early in infection when viral replication is the dominant driver
D) Patients with no supplemental oxygen requirement
E) Patients requiring supplemental oxygen or mechanical ventilation
ANSWER: E
Rationale:
The benefit of dexamethasone in COVID-19 was concentrated in patients who required respiratory support; the mortality reduction was greatest in those needing mechanical ventilation and present, though smaller, in those needing supplemental oxygen alone. This illustrates the principle that the anti-inflammatory benefit of glucocorticoids in infectious respiratory failure applies when dysregulated host inflammation, rather than active viral replication, is the dominant driver of organ injury. This makes Option E correct.
Option A: Option A is incorrect because the benefit was not uniform across all hospitalized patients; those without an oxygen requirement did not benefit.
Option B: Option B is incorrect because the trial addressed hospitalized patients, and mild non-hospitalized disease was not the population that benefited.
Option C: Option C is incorrect because early infection dominated by viral replication is precisely the setting where glucocorticoids showed no benefit and a trend toward harm.
Option D: Option D is incorrect because patients with no supplemental oxygen requirement showed no benefit and a non-significant trend toward harm, the opposite of the group that benefited.
13. In transplant immunosuppression, glucocorticoids are combined with calcineurin inhibitors (CNIs) such as tacrolimus or cyclosporine. What is the pharmacological basis for the synergy of this combination against alloreactive T cells?
A) Both drugs block the same calcineurin-NFAT step, doubling inhibition at one point
B) The CNI blocks calcineurin-NFAT-driven interleukin-2 (IL-2) gene transcription, while the glucocorticoid suppresses upstream cytokine signaling and T cell activation, so IL-2-dependent T cell expansion is inhibited at more than one level
C) Glucocorticoids increase calcineurin activity, which the CNI then blocks
D) The CNI provides anti-inflammatory transrepression while the glucocorticoid inhibits calcineurin directly
E) Both agents act solely by inducing apoptosis of mature peripheral T cells
ANSWER: B
Rationale:
Calcineurin inhibitors block the calcineurin-NFAT (nuclear factor of activated T cells) pathway that drives interleukin-2 (IL-2) gene transcription. Glucocorticoids act through broad suppression of T cell activation, including reduced IL-2 production and downregulation of antigen presentation and costimulatory signaling. Because the two classes limit IL-2-dependent clonal expansion of alloreactive T cells at more than one level, their combination is synergistic. This makes Option B correct.
Option A: Option A is incorrect because the two drugs do not act at the same calcineurin-NFAT step; the synergy arises precisely because they act at different levels.
Option C: Option C is incorrect because glucocorticoids do not increase calcineurin activity.
Option D: Option D is incorrect because it reverses the mechanisms: the glucocorticoid, not the CNI, provides transrepression, and the CNI, not the glucocorticoid, inhibits the calcineurin pathway.
Option E: Option E is incorrect because apoptosis of mature peripheral T cells is not the sole or dominant shared mechanism in humans; redistribution and IL-2 suppression are central to the glucocorticoid contribution.
14. Beyond transcriptional repression, glucocorticoids reduce pro-inflammatory cytokine output through a post-transcriptional mechanism. Which action best describes this additional arm?
A) Induction of MAP kinase phosphatase-1 (MKP-1), which inactivates p38 MAPK and JNK and thereby accelerates the decay of cytokine messenger RNA
B) Direct cleavage of mature cytokine proteins in the extracellular space
C) Induction of annexin-A1 to block cytokine receptor binding
D) Stabilization of cytokine messenger RNA to prolong its half-life
E) Phosphorylation of NF-kappaB to enhance its nuclear export
ANSWER: A
Rationale:
Glucocorticoids induce MAP kinase phosphatase-1 (MKP-1), a phosphatase that dephosphorylates and inactivates the p38 MAPK and JNK pathways. Those kinases normally stabilize the messenger RNA of cytokines such as TNF-alpha and IL-6 by acting on AU-rich element binding proteins; by inactivating them, MKP-1 accelerates cytokine mRNA decay and lowers cytokine protein output independently of transcriptional repression. This post-transcriptional action makes Option A correct.
Option B: Option B is incorrect because glucocorticoids do not directly cleave secreted cytokine proteins.
Option C: Option C is incorrect because annexin-A1 acts on phospholipase A2 in the eicosanoid pathway and does not block cytokine receptor binding as a post-transcriptional mechanism.
Option D: Option D is incorrect because it states the opposite of the true effect: glucocorticoids destabilize, rather than stabilize, cytokine mRNA.
Option E: Option E is incorrect because glucocorticoid control of NF-kappaB occurs through tethering, IkappaB-alpha induction, and HDAC2 recruitment, not through phosphorylation that enhances nuclear export.
15. A patient over age 50 with giant cell arteritis (GCA) reports transient visual loss (amaurosis fugax). What is the most appropriate initial glucocorticoid management?
A) Begin low-dose oral prednisone 15 mg per day and titrate over weeks
B) Withhold glucocorticoids until temporal artery biopsy confirms the diagnosis
C) Start a topical ophthalmic corticosteroid
D) Initiate intravenous methylprednisolone pulse therapy immediately, before oral prednisone, to prevent irreversible vision loss
E) Use inhaled corticosteroids to limit systemic exposure
ANSWER: D
Rationale:
Giant cell arteritis with visual symptoms is an emergency because anterior ischemic optic neuropathy can cause permanent blindness, and even a short delay in treatment may result in irreversible vision loss. The appropriate action is to start intravenous methylprednisolone pulse therapy immediately, before transitioning to high-dose oral prednisone, rather than waiting for confirmatory testing. This makes Option D correct.
Option A: Option A is incorrect because low-dose prednisone with slow titration is inadequate for sight-threatening GCA, which requires high-dose therapy; low-dose regimens are used for polymyalgia rheumatica, not for GCA with visual involvement.
Option B: Option B is incorrect because treatment must not be delayed for biopsy when vision is threatened; biopsy can still show vasculitis after glucocorticoids are started.
Option C: Option C is incorrect because topical ophthalmic corticosteroids do not treat the systemic large-vessel vasculitis driving the ischemia.
Option E: Option E is incorrect because inhaled corticosteroids deliver airway-targeted drug and provide no meaningful systemic anti-inflammatory coverage for vasculitis.
16. Glucocorticoids disrupt bone remodeling in a way that promotes net bone loss. Which change in the RANKL/OPG (receptor activator of nuclear factor kappa-B ligand / osteoprotegerin) system underlies this effect?
A) Decreased RANKL and increased OPG, shifting toward bone formation
B) Increased OPG with unchanged RANKL, neutralizing osteoclast activity
C) Increased RANKL expression with reduced OPG, favoring osteoclast differentiation and net bone resorption
D) Loss of both RANKL and OPG, halting all bone turnover
E) Conversion of OPG into an osteoclast-activating ligand
ANSWER: C
Rationale:
Glucocorticoids increase RANKL expression by osteoblasts and stromal cells while reducing expression of OPG, the decoy receptor that normally neutralizes RANKL. Because RANKL drives osteoclast differentiation and activation, this shift favors bone resorption; at the same time glucocorticoids suppress osteoblast differentiation and promote osteoblast apoptosis, reducing formation. The combined imbalance produces net bone loss, making Option C correct.
Option A: Option A is incorrect because it reverses the direction of change; glucocorticoids raise RANKL and lower OPG rather than the opposite.
Option B: Option B is incorrect because OPG falls rather than rises, and RANKL is not unchanged.
Option D: Option D is incorrect because turnover is not halted; resorption is actively favored over formation.
Option E: Option E is incorrect because OPG functions as a decoy receptor and is not converted into an osteoclast-activating ligand.
17. A postoperative patient on chronic glucocorticoid therapy develops hypotension that does not respond to fluids and vasopressors, along with hyponatremia but no hyperkalemia. Applying the concepts of glucocorticoid agent selection and adrenal physiology established earlier, what is the most appropriate immediate action?
A) Withhold glucocorticoids and await a random cortisol result before treating
B) Give empiric intravenous hydrocortisone 100 mg without waiting for cortisol testing, drawing a pre-dose cortisol if timing allows
C) Administer high-dose dexamethasone as the first-line agent for suspected crisis
D) Start fludrocortisone to correct the hyponatremia
E) Continue fluids and vasopressors alone, since steroid coverage is rarely needed
ANSWER: B
Rationale:
Refractory hypotension out of proportion to blood loss, unresponsive to fluids and vasopressors, with hyponatremia and no hyperkalemia in a patient on chronic glucocorticoids is the classic picture of perioperative adrenal crisis from a suppressed HPA axis. Secondary adrenal insufficiency spares mineralocorticoid output, which is why hyperkalemia is absent. Empiric intravenous hydrocortisone 100 mg should be given without awaiting cortisol testing, and a pre-dose random cortisol can be drawn for retrospective diagnosis if it does not delay treatment. This makes Option B correct.
Option A: Option A is incorrect because withholding treatment to wait for laboratory results risks a fatal but preventable crisis; the testing should not delay therapy.
Option C: Option C is incorrect because hydrocortisone, not dexamethasone, is the conventional agent for acute crisis coverage, as it provides the cortisol-equivalent activity needed; dexamethasone is reserved for situations where avoiding assay interference is specifically required and is not first-line here.
Option D: Option D is incorrect because fludrocortisone is an oral mineralocorticoid for chronic replacement and does not address acute glucocorticoid-deficient crisis; secondary insufficiency does not involve mineralocorticoid deficiency.
Option E: Option E is incorrect because continuing fluids and pressors alone ignores the specific and urgent need for glucocorticoid replacement in adrenal crisis.
18. Using the dose-duration risk framework for HPA suppression, which patient scheduled for major surgery should receive full stress-dose glucocorticoid supplementation?
A) A patient taking prednisone 4 mg per day for 2 weeks
B) A patient who stopped glucocorticoids 6 months ago with no documented adrenal atrophy
C) A patient who used a 5-day course of prednisone 1 month ago and is now off therapy
D) A patient on inhaled corticosteroid at a low dose for mild asthma
E) A patient taking prednisone 25 mg per day for the past 2 months
ANSWER: E
Rationale:
Patients taking more than 20 mg of prednisone equivalent per day for more than 3 weeks (or any patient with Cushingoid features) are presumed to have substantial HPA suppression and should receive full stress-dose supplementation for major procedures. A patient on prednisone 25 mg per day for 2 months meets this threshold, making Option E correct.
Option A: Option A is incorrect because prednisone less than 5 mg per day for only 2 weeks produces minimal suppression and requires no supplementation beyond the usual dose.
Option B: Option B is incorrect because a patient off glucocorticoids for more than 3 months with no documented adrenal atrophy is generally presumed to have recovered HPA function.
Option C: Option C is incorrect because a brief 5-day course taken a month earlier, with the patient now off therapy, does not meet the high-dose, prolonged-duration criterion for presumed suppression.
Option D: Option D is incorrect because low-dose inhaled corticosteroid for mild asthma carries minimal systemic HPA suppression and does not mandate full stress-dose coverage.
19. Based on the major septic shock trials and current synthesis, in which situation is low-dose hydrocortisone most appropriate?
A) Septic shock that remains refractory despite adequate fluid resuscitation and escalating vasopressor requirement
B) Any patient with sepsis at the time of diagnosis, regardless of hemodynamics
C) Septic shock that responds promptly to initial fluid resuscitation
D) As a substitute for antibiotics in the management of the infection
E) Only after a short ACTH stimulation test identifies a responder subgroup
ANSWER: A
Rationale:
The synthesis of the CORTICUS, ADRENAL, and APROCCHSS trials supports low-dose hydrocortisone (about 200 mg per day) for septic shock that remains refractory after adequate fluid resuscitation and with a high, escalating vasopressor requirement, rather than for sepsis broadly. This makes Option A correct.
Option B: Option B is incorrect because glucocorticoids are not indicated for all sepsis at diagnosis; the benefit is limited to refractory shock, not hemodynamically stable patients.
Option C: Option C is incorrect because patients who respond to initial resuscitation should not receive hydrocortisone, as the trials showed no benefit in that group.
Option D: Option D is incorrect because glucocorticoids are adjunctive and never replace antimicrobial therapy for the underlying infection.
Option E: Option E is incorrect because the CORTICUS trial specifically found that the short ACTH stimulation test did not identify a subgroup who benefited, so it is not used to select patients for hydrocortisone.
20. For peritumoral cerebral edema, dexamethasone is preferred over hydrocortisone. Drawing on the comparative properties of these agents, which combination of features best explains that preference?
A) High mineralocorticoid activity and short duration permitting rapid titration
B) Low potency requiring large volumes that improve cerebral perfusion
C) Rapid hepatic clearance that limits central nervous system accumulation
D) High glucocorticoid potency, negligible mineralocorticoid activity that avoids worsening fluid retention, and a long duration of action permitting convenient dosing
E) Selective mineralocorticoid receptor agonism that reduces vascular permeability
ANSWER: D
Rationale:
Dexamethasone is preferred for cerebral edema because it combines high glucocorticoid potency, negligible mineralocorticoid activity (so it does not aggravate sodium and water retention in patients at risk of raised intracranial pressure and volume overload), and a long duration of action that allows convenient divided dosing; mechanistically it also reduces VEGF-driven vascular permeability in peritumoral tissue. This makes Option D correct.
Option A: Option A is incorrect because dexamethasone has negligible, not high, mineralocorticoid activity and a long, not short, duration of action.
Option B: Option B is incorrect because dexamethasone is high-potency, and the rationale for its use does not involve large fluid volumes to improve perfusion.
Option C: Option C is incorrect because dexamethasone is long-acting rather than rapidly cleared; its persistence is part of why it is convenient.
Option E: Option E is incorrect because the benefit derives from glucocorticoid receptor effects, not selective mineralocorticoid receptor agonism, which dexamethasone essentially lacks.
21. The favorable local-to-systemic ratio of inhaled corticosteroids depends on a pharmacokinetic dissociation. Which pair of mechanisms best accounts for high airway drug concentration with low systemic exposure?
A) High oral bioavailability with slow hepatic metabolism
B) Rapid renal excretion of unchanged drug with low protein binding
C) Poor gastrointestinal absorption of the swallowed fraction together with extensive first-pass hepatic metabolism of absorbed drug
D) Active transport of drug out of the systemic circulation back into the airway
E) Conversion of the drug to a more systemically active metabolite in the liver
ANSWER: C
Rationale:
Inhaled corticosteroids achieve high local airway concentrations with limited systemic effect through two complementary mechanisms: the swallowed fraction is poorly absorbed from the gastrointestinal tract, and the fraction that is absorbed undergoes extensive first-pass hepatic metabolism. The result is that little active drug reaches the systemic circulation while a high concentration acts locally in the airway. This makes Option C correct.
Option A: Option A is incorrect because high oral bioavailability with slow metabolism would increase, not minimize, systemic exposure, defeating the design goal.
Option B: Option B is incorrect because the dissociation depends on gut absorption and first-pass metabolism rather than rapid renal excretion of unchanged drug.
Option D: Option D is incorrect because there is no active transport pump returning systemic drug to the airway; the selectivity comes from absorption and metabolism, not from re-uptake.
Option E: Option E is incorrect because conversion to a more systemically active metabolite would raise systemic activity, whereas agents like ciclesonide are instead activated locally in the airway to enhance topical selectivity.
22. A patient on systemic glucocorticoids has an elevated neutrophil count, which earlier in this set was explained as a benign demargination effect. Which additional peripheral smear finding would best distinguish a superimposed bacterial infection from the expected steroid-induced neutrophilia?
A) An eosinophil count that is suppressed
B) A lymphocyte count that is reduced
C) A neutrophil count that is mildly elevated
D) A monocyte count that is reduced
E) A left shift with immature band forms and toxic granulation on the peripheral smear
ANSWER: E
Rationale:
Steroid-induced neutrophilia reflects demargination and release of mature neutrophils from marrow storage, without a true left shift. A superimposed bacterial infection, by contrast, produces a left shift with immature band forms and toxic granulation, which signals active marrow response to infection beyond the expected steroid effect. This discriminating finding makes Option E correct.
Option A: Option A is incorrect because a suppressed eosinophil count is the expected glucocorticoid effect and does not indicate infection.
Option B: Option B is incorrect because reduced lymphocytes reflect the expected steroid-induced redistribution rather than a marker distinguishing infection.
Option C: Option C is incorrect because a mildly elevated neutrophil count is exactly what the steroid alone produces and cannot by itself separate infection from drug effect.
Option D: Option D is incorrect because monocytopenia is part of the expected glucocorticoid pattern and is not a sign of superimposed infection.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.